<DOC>
	<DOCNO>NCT00184028</DOCNO>
	<brief_summary>This research study subject squamous cell cancer head neck solely treatable surgery radiation . This research study involve treatment experimental chemotherapy combination oxaliplatin Taxotere . Tha main purpose study assess effectiveness combination medication type cancer . Approximately 54 subject take part study .</brief_summary>
	<brief_title>Combination Taxotere Oxaliplatin Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must histologically cytologically confirm Head Neck Squamous Cell Carcinoma metastatic unresectable standard curative palliative measure exist longer effective . Tissue tumor must available . This may paraffin embedded tissue previous biopsy/resection . If available , repeat biopsy must perform . Age great equal 18 year ECOG performance status less equal 2 ( Karnofsky great equal 50 % ) Patients must adequate organ marrow function define : leukocyte great equal 3,000/microliter hemoglobin great equal 8.0 g/dl absolute neutrophil count great equal 1,500/microliter platelet great equal 100,000/microliter total bilirubin within normal institutional limit creatinine within normal institutional limit OR creatinine clearance great equal 60 mL/min/1.73 m2 patient creatinine level institutional normal If : ALK PHOS less equal ULN AST ALT less equal ULN , patient eligible . ALK PHOS less equal ULN AST ALT great 1x less equal 1.5x , patient eligible . ALK PHOS less equal ULN AST ALT great 1.5x less equal 5x , patient eligible . ALK PHOS less equal ULN AST ALT great 5x ULN , patient ineligible . ALK PHOS great 1x less equal 2.5x AST ALT less equal ULN , patient eligible . ALK PHOS great 1x less equal 2.5x AST ALT great 1x less equal 1.5x , patient eligible . ALK PHOS great 1x less equal 2.5x AST ALT great 1.5x less equal 5x , patient ineligible . ALK PHOS great 1x less equal 2.5x AST ALT great 5x ULN , patient ineligible . ALK PHOS great 2.5x less equal 5x ALT AST less equal ULN , patient eligible . ALK PHOS great 2.5x less equal 5x ALT AST great 1x less equal 1.5x , patient ineligible . ALK PHOS great 2.5x less equal 5x ALT AST great 1.5x less equal 5x , patient ineligible . ALK PHOS great 2.5x less equal 5x ALT AST great 5x ULN , patient ineligible . ALK PHOS great 5x ULN AST ALT less equal ULN , patient ineligible . ALK PHOS great 5x ULN AST ALT great 1x less equal 1.5x , patient ineligible ALK PHOS great 5x ULN AST ALT great 1.5x less equal 5x , patient ineligible ALK PHOS great 5x ULN AST ALT great 5x ULN , patient ineligible Patients neuropathy &lt; 1 . Ability understand willingness sign write informed consent document Women childbearing potential must negative pregnancy test Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter Patients chemotherapy radiotherapy within 4 week prior enter study Patients undergo therapy investigational agent . Previous treatment involve regimen utilize protocol chemotherapeutic agent Patients know brain metastasis History allergy platinum compound antiemetic appropriate administration conjunction protocoldirected chemotherapy . Patients history severe hypersensitivity reaction Taxotere Oxaliplatin drug formulate polysorbate 80 Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Pregnant nursing woman HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>